# THE 24TH ANNUAL NAPA PAIN CONFERENCE

CALL FOR ABSTRACTS

THE MERITAGE RESORT AND CONFERENCE CENTER, NAPA VALLEY, CALIFORNIA







## SHARE YOUR WORK AT THE $24^{\text{TH}}$ ANNUAL NAPA PAIN CONFERENCE AUGUST 18-20 AT THE MERITAGE, NAPA VALLEY

ABSTRACT DEADLINE: MAY 8, 2017, 11:59 PM PDT

Submissions are **open** for abstracts to be considered for oral presentations and posters at the Napa Pain Conference. Share your research, clinical outcomes, quality improvement initiative, practice improvement, or patient care strategy at one of the nation's oldest and most prestigious pain conferences.

#### **Oral Presentations**

Accepted presentations will receive complimentary registration for the presenting author and the option to present a poster of their work.

#### **Posters**

Accepted posters will be eligible for awards and prizes.

#### **Completing Your Abstract**

Submission details, categories, guidelines and tips are included inside. Finished abstracts must be received in .pdf or Word format via email to **Education@Neurovations.com** by 11:59 PM, PDT, Monday, May 8, 2017.

#### **Conference Dates**

August 18-20, 2017

#### Location

The Meritage Resort & Convention Center 875 Bordeaux Way Napa, CA 94558

## CATEGORIES

The Program Committee is accepting original abstracts in the following categories:

- Quality Improvement (QI) initiatives undertaken at your institution that improved clinical care, service, cost or patient outcomes
- · Clinical advancements in pain management
- · Therapeutic options for acute or chronic pain
- Improving patient communications and/or adherence to treatment plans
- · Safe prescribing
- Cancer pain
- Targeted drug delivery
- Bioelectronic medicine, including neurostimulation
- Regenerative medicine
- Opioid use disorder and overdose treatment, including buprenorphine and naloxone
- Advances in practice management, including implementation of EHR and transitioning to ICD-10

Indicate your content category when submitting your abstract. This will help the Program Committee to assign your abstract to the most appropriate reviewers, and to construct unified and logical sessions at the conference.

If necessary, include a second category to ensure that your abstract is sent to the optimal combination of reviewers relevant to the content of your abstract. Not every abstract fits neatly into a single category and the identification of a secondary category might be helpful during the review and program construction process.

## AWARDS

Awards and prizes will be presented to the three top-ranked posters at the conference. Posters must be displayed at the conference and staffed during scheduled discussion times in order to qualify.

#### 1st Place

\$1,000 and 1<sup>st</sup> place award + complimentary registration for the Primary Author to attend the 25<sup>th</sup> Annual Napa Pain Conference.

#### 2<sup>nd</sup> Place

\$750 and 2<sup>nd</sup> place award + complimentary registration for the Primary Author to attend the 25<sup>th</sup> Annual Napa Pain Conference.

#### 3rd Place

\$500 and 3rd place award

## STRUCTURE

#### **Synopsis**

A synopsis, limited to 100-words, must be included for each abstract. The synopsis can appear on a separate page and will not be counted against page limits.

Your synopsis should include a brief summary of the problem, methods, results, and conclusions. Synopses must only include text, without equations or images, and be without references or citations to items described in the full abstract.

#### **Abstract Format**

Please note: this is a guideline. We understand that some abstracts will not necessarily lend themselves to this format

Do your best to fit the abstract on a single page. This page does not need to include the synopsis.

Address each of the following sections within the abstract. In each section, answer the question listed below. (Do not repeat the actual question in the body of your abstract.)

Title "What do you call this project/poster?"

**Content** "What content area best fits your abstract?"

Purpose "Why was this study/research performed?"

Methods "How has this problem been studied?"

**Results** "What was the outcome or principal data and statistical analysis?"

**Discussion** "What is the relevance to clinical practice or future research?"

References should use the suggested style below.

**Disclosure** Work submitted for presentation must include an acknowledgment of funding

sources of commercial nature, and/or consulting or holding of significant equity in a company that could be affected by the results of the study. Even if indicated elsewhere in the abstract, this must appear as the last sentence of the abstract and read "funded by..." and/or "equity in...". If nothing to disclose, state "Nothing to disclose by any author(s)." Disclosure of funding and/or relationships must not

include company logos (text only).

#### **Authors**

List all authors in the format below. Author information will not be included in the single page limit.

#### SUBMITTING AUTHOR

Name:

Company:

Mailing Address:

Phone Number:

Email:

#### ADDITIONAL AUTHOR(S)

Include information for all authors

Name:

Company:

Mailing Address:

Phone Number:

Email:

#### PRESENTING AUTHOR (if different)

Name: Company:

Mailing Address:

Phone Number:

Email:

#### CITATIONS IN THE BODY OF THE PAPER

Cite each source in numerical order using superscript Arabic numerals (1, 2, 3...).

Example 1: A review of regulations has been complete by the WHO.15

Example 2: The data were as follows  $^{3,4}$ :

Example 3: As previously reported, 11-14, 25

#### CITATIONS IN THE REFERENCE LIST

List references numerically in the order by which they were cited in the text.

Example 1: 1. Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004;61(7):1025 1029.

Example 2: 2. Weiss R. The promise of precision prescriptions. Washington Post. June 24, 2000:A1. www.washingtonpost.com. Accessed October 10, 2001.

## INSTRUCTIONS

#### Submit Abstracts via Email

Abstracts must be submitted electronically to Education@Neurovations.com

#### **Subject Line**

Title your subject line "NPC24 Abstract: [Add your title]"

#### **Due Date**

Monday, March 8, 2017 by 11:59 pm, PDT

#### File Formats

Adobe .pdf or Microsoft Word

#### Include

- Authors list
- Synopsis
- 1-page Abstract

#### **Authorization**

The submitting author verifies, by virtue of submitting the abstract, that <u>all</u> authors agree:

- to the submission of the abstract to the Napa Pain Conference
- that the abstract constitutes an original work
- that copyright permissions have been secured (as necessary) for included material
- the abstract includes valid, accurate, and balanced content

Submission of an abstract constitutes a commitment by the author(s) to present their work if accepted.

A presenting author of each abstract must register for the Napa Pain Conference. Submission of an abstract does not automatically register you for the conference.

Expenses associated with the presentation of an abstract are the responsibility of the presenter. This includes the production of printed posters. However, poster boards and push-pins will be available for poster presenters, and A/V will be provided for oral presentations.

If selected, your presentation/poster is expected to reflect the contents of your abstract. Substantial deviation from the published abstract or failure to present may jeopardize acceptance for future abstracts.

## TIPS

#### **Proofread**

Proofread your abstract to identify and correct any errors before submission.

The committee grades concise and clear abstracts more highly than long or disorganized ones. You have limited space, so make every word count. Misspellings and typographical errors reflect poorly upon your research.

#### Follow the Instructions

Part of the grading includes organization and clarity. Follow the Instructions and Structure to give your abstract the best chance during review and selection.

#### Think "New"

Novel, innovative, or recent discoveries or improvements will be weighted higher. However, there is always a place for best practices with good outcomes.

#### "Show Me The Data"

Support your abstract with appropriate evidence. Robustness of evidence and analysis is the most important factor for a well-received abstract.

If you have the information, make sure to include: sample size, significance, study/observation duration, follow-up.

Regardless of design or the central thesis of the abstract, ensure that there is sufficient evidence to support your conclusions.

## GENERAL INFORMATION

#### **All Abstracts**

- There is no limit to the number of abstracts an author may submit for consideration.
- A presenting author of each abstract must register for the Napa Pain Conference. Submission of an abstract does not
  automatically register you for the conference.
- · Abstracts submitted to, or presented at other societies or national meetings may only be submitted for consideration if:
  - 1. The prior submission is not currently under review by the other organization;
  - 2. You have retained copyright authority vs. transferring copyright to the previous entity; and
  - You disclose prior publication as part of the abstract, as this must be considered in scoring abstracts for presentations and awards.
- All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine
  as adequate justification for their indications and contraindications in the care of patients.
- All submissions must be HIPAA-compliant. Patient confidentiality must be protected. No names, hospital ID numbers or any
  other identifying information can appear in your presentation.
- All scientific research referred to, reported or used in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection and analysis.
- A person who is employed by a "commercial interest" (defined as any entity producing, marketing, re-selling, or distributing
  health care goods or services consumed by, or used on, patients) cannot speak if the CME content relates to the business lines and
  products of its employer. However, industry employees are encouraged to submit "poster-only" abstracts. Posters are not part of
  the CME content and are a great way to convey the latest research and developments.
- · A presenter is not to receive financial support in conjunction with their presentation(s) except from their employer.
- In submitting an abstract, all authors retain copyright to the content and agree to grant SpectrumCare/Neurovations Education a limited, nonexclusive, royalty-free license to present and reproduce the content online, in print, and in other media or publications associated with its educational programs, and to archive the content online and in other means. SpectrumCare/Neurovations Education agrees not to sub-license the content to a third party.

#### **Posters**

- Posters will be displayed throughout the entirety of the conference.
- Authors will be asked to present their posters and be available for questions at assigned times.
- Poster awards will be announced at the morning announcements Sunday, August 20.
- Poster presentations are limited to a single presenter, but abstracts can have multiple authors.
- List the affiliations for all authors, such as universities and other institutions.

## ABSTRACT SELECTION

In order to be selected for an oral presentation, abstracts must:

- · receive high marks by the reviewers;
- align with other presentations; and
- be submitted by authors/organizations which can present content for CME credit.

Abstracts submitted without data, because investigations or analyses are incomplete, will be evaluated only on the basis of the information contained within the abstract. Reviewer scores and comments are confidential and will not be made available to anyone (including authors) outside of the immediate review process.

#### **Notification**

The outcome of each abstract's review will be emailed to the primary author listed within the abstract by May 26, 2017.

#### **Review Criteria**

#### Innovation/novelty

Advancement of knowledge, and/or improvement of capabilities.

#### Quality

All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

Data/outcomes should be substantive and not just implied. When possible, comprehensive statistical analysis should be applied. Images and spectra should be of the highest quality.

#### Impact

The method or data in the abstract should aim to advance or change the field or the behavior of clinicians in significant ways.

#### Bias

Bias in favor of a particular product or company is grounds for rejection.

Use of a particular company's products or equipment in itself does not represent bias. Likewise, research involving a single method, drug, or device would not constitute bias if it conforms to best practices of study design and analysis. Nondata-driven statements of superiority, however, would be considered biased.

#### Repetition of Content

Multiple submissions of the same or nearly the same abstract by the same author(s)/institution(s) is grounds for rejection of all submitted abstracts from the offending parties.

#### Clarity

Organization, presentation, structure, readability

Tips: Proofread your abstract before submission. Avoid abbreviations. Type in sentence case.

## **PRESENTATIONS**

#### **Oral Presentations**

After initial grading, authors of abstracts under consideration for oral presentations will be required to complete additional author information and disclosure forms. If accepted as an oral presentation, the presenting author will receive complementary registration to the conference. Additional expenses, including but not limited to housing and travel, will remain the responsibility of the presenter.

#### **Poster Preparation**

Authors of accepted abstracts are expected to produce a traditional poster for display.

An author must be present to stand with each poster during assigned poster times to answer questions and discuss the work.

A PDF of your final poster will be required by Tuesday, August 1 for later publication on the conference website.

Authors are responsible for production (including costs) of their poster.

#### **Printed Posters**

Maximum poster size: 48" high x 60" wide.

Posters must contain:

- 1. Rationale for the research/initiative
- 2. Methods
- 3. Results
- 4. Conclusions
- 5. Necessary figures
- 6. Author information, including affiliations
- 7. Information on funding and organizational affiliations, without using company logos (text only)

#### **Publication**

Accepted abstracts will made available online by August 11, 2017.

#### Failure to Present

Submission of an abstract is considered a commitment to produce a poster and present the abstract if it is accepted. Failure to present an abstract may jeopardize future submissions by the same author or institution.

#### Confidentiality

Submitted abstracts are treated as confidential from the time of submission to the publication date of August 11, 2017.

## SUBMISSION CHECKLIST

Due DateMonday, May 8 by 11:59pm PDTEmailed toEducation@Neurovations.comSubject LineNPC24 Abstract: [Title]

**Did you...** Proofread your abstract?

Ensure that it is HIPAA compliant? Include each content category?

Secure copyright (as needed) for any content in your abstract?

Save it as a PDF or Word file?

Great. We look forward to reviewing your abstract and seeing you in Napa!

## PROGRAM COMMITTEE

#### INVITED FACULTY

#### MARKO BODOR, MD

Founder, Interventional Spine and Sports Medicine Private Practice, Bodor Clinic

#### AARON K. CALODNEY, MD

Director of Clinical Research, Precision Spine Care, Texas Spine and Joint Hospital; 2017 President, ASIPP

#### ELIOT S. KRAMES, MD, DABPM

Founding Editor, Emeritus Editor-in-Chief, Neuromodulation

#### SEAN LI, MD

Premier Pain Centers, New Jersey

#### BERNARD F. MORREY, MD

Emeritus Chair of the Department of Orthopedics, and the John and Posy Krehbiel Professor of Orthopaedic Surgery, Mayo Clinic

#### AVINASH RAMCHANDANI, MD. MBA

#### RICHARD M. ROSENTHAL. MD

Medical Director, Nexus Pain Care; Editor, *Practical Pain Management* 

#### MICHAEL SAULINO, MD, PhD

Clinical Director, Intrathecal Therapy Services. MossRehab

#### GREGORY SCHERRER, PhD. PharmD

Assistant Professor of Anesthesiology, Perioperative and Pain Medicine and Neurosurgery, Stanford University

#### ASHBY WOLFE, MD, MPP, MPH

Chief Medical Officer, Centers for Medicare & Medicaid Services, Region IX

#### GEORGE C. CHANG CHIEN, DO

Medical Director of Pain Management, Ventura County Medical Center

#### PENNEY COWAN

Founder & CEO, American Chronic Pain Association

#### TIMOTHY T. DAVIS. MD

Founder & Medical Director, Orthopedic Pain Specialists

#### LEO KAPURAL, MD, PhD

Professor of Anesthesiology, Wake Forest University; Pain Physician, Carolinas Pain Institute and Center for Research

#### STEN LINDAHL, MD, PhD, FRCA

Chair 2001 - 2002 of the Nobel Committee; Member, the Nobel Assembly for the Nobel Prize in Physiology or Medicine 1996 - 2012; Professor Emeritus, Karolinska Institutet

#### GAIL McGLOTHLEN, DNP, RN

#### LAWRENCE POREE, MD, PhD, MPH

Clinical Professor, Department of Anesthesia and Director of Neuromodulation Services, University of California at San Francisco

#### DAVID PROVENZANO, MD

Pain Diagnostics & Interventional Care, Heritage Valley Health System

#### SAMIR J. SHETH, MD

Director of Neuromodulation, University of California, Davis

#### B. TODD SITZMAN, MD, MPH

Medical Director, Advanced Pain Therapy, PLLC

#### LISA STEARNS, MD

Founder & Medical Director, Center for Pain and Supportive Care; Founder, Valley Cancer Pain Foundation